Heirloom Wealth Management Grows Stock Holdings in Novo Nordisk A/S $NVO

Heirloom Wealth Management lifted its position in Novo Nordisk A/S (NYSE:NVO) by 66.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 138,715 shares of the company’s stock after buying an additional 55,618 shares during the period. Novo Nordisk A/S makes up about 1.9% of Heirloom Wealth Management’s portfolio, making the stock its 21st largest position. Heirloom Wealth Management’s holdings in Novo Nordisk A/S were worth $7,697,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Jennison Associates LLC increased its position in shares of Novo Nordisk A/S by 0.3% during the second quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock worth $1,303,466,000 after purchasing an additional 63,341 shares in the last quarter. Loomis Sayles & Co. L P grew its stake in Novo Nordisk A/S by 1.5% during the 2nd quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock valued at $867,998,000 after purchasing an additional 187,789 shares during the last quarter. Folketrygdfondet increased its holdings in shares of Novo Nordisk A/S by 1.2% in the third quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock valued at $566,659,000 after purchasing an additional 117,370 shares during the period. Sustainable Growth Advisers LP lifted its holdings in shares of Novo Nordisk A/S by 11.7% during the second quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock worth $427,416,000 after purchasing an additional 649,390 shares during the period. Finally, State Street Corp boosted its position in Novo Nordisk A/S by 0.8% in the second quarter. State Street Corp now owns 6,047,683 shares of the company’s stock valued at $418,231,000 after buying an additional 47,430 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NVO has been the subject of several research reports. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday. Citigroup assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 3rd. Finally, Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Seven investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $56.07.

Novo Nordisk A/S Stock Down 16.3%

Shares of NYSE NVO opened at $39.68 on Tuesday. The firm has a market cap of $177.16 billion, a price-to-earnings ratio of 11.43 and a beta of 0.67. The company’s 50-day simple moving average is $53.56 and its 200-day simple moving average is $53.23. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 52-week low of $39.34 and a 52-week high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 23.63%.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Early-stage pipeline win — a China Phase 2 trial of the triple‑agonist UBT251 (GLP‑1/GIP/glucagon), developed with United Biotechnology, showed up to 19.7% mean weight loss at 24 weeks and a tolerability profile consistent with incretin therapies, which could expand Novo’s future product set beyond current semaglutide franchises. Novo Nordisk, United Biotechnology obesity drug trial shows 19.7% weight loss
• Neutral Sentiment: Wegovy/Ozempic revenue momentum remains a structural positive for the company even as sentiment sours on the pipeline; some analysts still point to strong product sales and long‑term growth from existing GLP‑1 offerings. Novo Nordisk: Why Wegovy Growth Beats Wall Street Expectations
• Negative Sentiment: Major clinical setback — CagriSema failed to demonstrate non‑inferiority to Eli Lilly’s tirzepatide (Zepbound/Mounjaro) in the pivotal REDEFINE‑4 head‑to‑head trial, showing weaker weight‑loss results over the trial period; this directly threatens Novo’s ability to defend/expand market share in the most valuable obesity segment. Novo Nordisk’s obesity drug falls short against Eli Lilly’s in Copenhagen trial
• Negative Sentiment: Quantified underperformance and market impact — reported REDEFINE‑4 numbers (e.g., ~20.2% weight loss for CagriSema vs ~23.6% for tirzepatide over 84 weeks) and the head‑to‑head loss triggered heavy selling, wiping out recent Wegovy‑era gains and pushing the stock to multi‑year lows. Novo Nordisk Shares Drop 15% After CagriSema Misses Phase 3 Goal
• Negative Sentiment: Analyst and rating pressure — at least one sell‑side analyst publicly said he’s “thrown in the towel” and firms including Deutsche Bank moved to downgrade NVO, increasing near‑term sell pressure and reducing conviction among institutional holders. Analyst says he’s thrown in the towel on Novo Nordisk after latest setback
• Negative Sentiment: Legal/investor actions — multiple law firms and investor‑representation announcements and fraud‑investigation notices have appeared, which can prolong uncertainty and pressure sentiment even if no formal enforcement action is taken. NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.